TD Cowen Initiates Coverage On Reata Pharmaceuticals with Outperform Rating, Announces Price Target of $140
Portfolio Pulse from richadhand@benzinga.com
TD Cowen analyst Tyler Van Buren has initiated coverage on Reata Pharmaceuticals (NASDAQ:RETA) with an Outperform rating and a price target of $140.
July 06, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals has been given an Outperform rating by TD Cowen, with a price target of $140.
The Outperform rating from TD Cowen indicates a positive outlook for Reata Pharmaceuticals. The price target of $140 suggests a significant upside potential from the current price. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100